Qiagen acquires Ingenuity Systems

Qiagen has announced the acquisition of Ingenuity Systems, a provider of software solutions that efficiently and accurately analyse and interpret the biological meaning of genomic data.

Ingenuity, a privately held US company based in California’s Silicon Valley, has created a knowledge system of biomedical information and analysis solutions for the exploration, interpretation and analysis of complex biological systems. The Ingenuity Knowledge Base and software applications enable users to accurately interpret the meaning of increasingly large amounts of biological data to better guide scientific experiments and medical treatment decisions.

“The interpretation of biological information is becoming a cornerstone of Qiagen’s ecosystem of sample and assay technologies for molecular testing - both in life sciences research and in diagnostics,” said Peer M Schatz, Chief Executive Officer of Qiagen.

“Integration of Ingenuity’s solutions into a powerful, full-range ecosystem of Qiagen’s molecular testing solutions, such as PCR and next-generation sequencing, promises to offer significant value to Qiagen customers and shareholders.”

“The Ingenuity mission from day one has been to accelerate scientific discovery and enhance clinical decision-making through a rich understanding of biological systems,” said Jake Leschly, President and CEO of Ingenuity Systems.

“As part of Qiagen, we will offer our biological knowledge content and software in the context of a best-in-class ecosystem of molecular testing solutions and to a greatly expanded range of customers around the world.”

Ingenuity will significantly expand and strengthen Qiagen’s own curated database, which is commercialised embedded in wet lab assays sold through Qiagen’s GeneGlobe content portal.

Many members of Ingenuity’s senior management team, including Leschly, will continue with Qiagen, and the offices will remain in California.